Participant flow14

How many started, completed or left each group, period by period.

1 to 14 of 14

Period	Milestone	Group	Participants
Overall Study	STARTED	Abemaciclib	270
Overall Study	STARTED	Erlotinib	183
Overall Study	Received at Least One Dose of Study Drug	Abemaciclib	265
Overall Study	Received at Least One Dose of Study Drug	Erlotinib	175
Overall Study	Off Treatment	Abemaciclib	246
Overall Study	Off Treatment	Erlotinib	172
Overall Study	Death Due to Any Cause	Abemaciclib	30
Overall Study	Death Due to Any Cause	Erlotinib	20
Overall Study	Progressive Disease	Abemaciclib	174
Overall Study	Progressive Disease	Erlotinib	137
Overall Study	COMPLETED	Abemaciclib	204
Overall Study	COMPLETED	Erlotinib	157
Overall Study	NOT COMPLETED	Abemaciclib	66
Overall Study	NOT COMPLETED	Erlotinib	26

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02152631/flow